The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin
Official Title: A Randomized Phase II Multi-centric Open Label Clinical Trial to Determine the Efficacy and Toxicity of Preoperative Chemotherapy With or Without Bevacizumab in Patients With Advanced Ovarian Cancer
Study ID: NCT01847677
Brief Summary: Recently results have shown that Bevacizumab is active both in monotherapy and in combination therapy in patients with ovarian cancer. One of our objectives is to evaluate whether the addition of neoadjuvant bevacizumab improves the response and whether this affects the evolution of patients.
Detailed Description: Epithelial ovarian cancer (OC) is the fourth leading cause of cancer death in women, after lung, breast and colon cancer, and it represents the most common cause of death from gynaecological malignancies. The high mortality associated with OC is due to the lack of screening tests that enable an early diagnosis, thus the majority of patients are diagnosed at advanced stages of the disease when the chances of a cure are very limited. In fact, the 5-year overall survival (OS) rate for stage III-IV OC does not exceed 20-30% in many series. The standard treatment for advanced OC is maximal cytoreductive surgery (or debulking) followed by the administration of 6 cycles of adjuvant chemotherapy with carboplatin and paclitaxel. In recent years, a number of studies have been carried out with antiangiogenic drugs. Specifically, bevacizumab, an anti-VEGF monoclonal antibody, has been shown to be active both in monotherapy and combination therapy in patients with OC that have received multiple previous lines of chemotherapy. One of the objectives is to evaluate whether the addition of neoadjuvant bevacizumab improves the response and whether this affects the evolution of patients.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Hospital La Fe, Valencia, Comunidad Valenciana, Spain
Hospital Germans Trias i Pujol, Badalona, , Spain
Hospital Clínic, Barcelona, , Spain
Hospital Sant Pau, Barcelona, , Spain
H. Reina Sofia, Cordoba, , Spain
ICO Girona, Girona, , Spain
ICO Hospitalet, Hospitalet del Llobregat, , Spain
Hospital 12 de Octubre, Madrid, , Spain
Hospital Clínico San Carlos, Madrid, , Spain
Hospital Universitario Morales Meseguer, Murcia, , Spain
Hospital Son Llatzer, Palma Mallorca, , Spain
Parc Taulí, Sabadell, , Spain
Hospital Marqués de Valdecilla, Santander, , Spain
Name: Yolanda García, MD
Affiliation: C.S Parc Taulí
Role: STUDY_CHAIR